MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2016 International Congress

    Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

    K. Schmeisser, A. Parker (Montreal, QC, Canada)

    Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…
  • 2016 International Congress

    Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders

    M.V. Rey, L. Molina, B. Recinos, B. Paz, M. Rovelo, F.E. Rodriguez Elias, J. Calderon, A. Arellano, S. Pomata, S. Perez-Lloret, CA-APD Study Team (Buenos Aires, Argentina)

    Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…
  • 2016 International Congress

    Frequency of echogenic abnormality of the substantia nigra is increased in methamphetamine users

    J.J. Rumpf, J. Albers, C. Fricke, D. Weise, J. Classen (Leipzig, Germany)

    Objective: To investigate structural abnormality of the substantia nigra (SN) in methamphetamine users using transcranial sonography (TCS). Background: Epidemiologic studies suggest that chronic use of…
  • 2016 International Congress

    Drug induced parkinsonism: Role of functional imaging and follow up

    A.S. Shetty, H.J. Shah, V.R. Lele, P.M. Wadia (Mumbai, India)

    Objective: Retrospective study of the outcome of patients with new onset parkinsonism with a history of exposure of a drug known to cause parkinsonism prior…
  • 2016 International Congress

    Valproate-induced reversible parkinsonism – A case series

    R.M. Simões, N. Inácio, V.B. Silva, A. Arraiolos, P. Alegria, N. Canas, J. Vale (Loures, Portugal)

    Objective: To describe a case series of valproate (VPA)-induced parkinsonism and increase awareness for this condition. Background: VPA as a cause of parkinsonism has been…
  • 2016 International Congress

    Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

    B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

    Objective: Characterization of extra-striatal manifestations in the 6-hydroxydopamine (6-OHDA) Parkinson's disease (PD) animal model. Background: PD is a neurodegenerative disorder characterized by progressive loss of…
  • 2016 International Congress

    A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

    S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

    Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…
  • 2016 International Congress

    Incidental finding of drug-induced movement disorder

    G. Avagyan, H. Manvelyan, A. Nazaryan (Yerevan, Armenia)

    Objective: Recognizing a drug-induced movement disorder is critical as only stopping using over the counter dopamine-blocking medications such as metoclopramide can reverse or improve clinical…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley